bioRxiv ScienceSearch

bioRxiv · 10.1101/413302

Brain age prediction of healthy subjects on anatomic MRI with deep learning: going beyond with an \"explainable AI\" mindset

Abstract

ObjectivesDefine a clinically usable preprocessing pipeline for MRI data\n\nPredict brain age using various machine learning and deep learning algorithms\n\nDefine Caveat against common machine learning traps\n\nData and MethodsWe used 1597 open-access T1 weighted MRI from 24 hospitals.\n\nPreprocessing consisted in applying : N4 bias field correction, registration to MNI152 space, white and grey stripe intensity normalization, skull stripping and brain tissue segmentation\n\nPrediction of brain age was done with growing complexity of data input (histograms, grey matter from segmented MRI, raw data) and models for training (linear models, non linear model such as gradient boosting over decision trees, and 2D and 3D convolutional neural networks).\n\nWork on interpretability consisted in (i) proceeding on basic data visualization like correlations maps between age and voxels value, and generating (ii) weights maps of simpler models, (iii) heatmaps from CNNs model with occlusion method.\n\nResultsProcessing time seemed feasible in a radiological workflow : 5 min for one 3D T1 MRI.\n\nWe found a significant correlation between age and gray matter volume with a correlation r = -0.74. Our best model obtained a mean absolute error of 3.60 years, with fine tuned convolution neural network (CNN) pretrained on ImageNet.\n\nWe carefully analyzed and interpreted the center effect.\n\nOur work on interpretability on simpler models permitted to observe heterogeneity of prediction depending on brain regions known for being involved in ageing (grey matter, ventricles). Occlusion method of CNN showed the importance of Insula and deep grey matter (thalami, caudate nuclei) in predictions.\n\nConclusionsPredicting the brain age using deep learning could be a standardized metric usable in daily neuroradiological reports. An explainable algorithm gives more confidence and acceptability for its use in practice. More clinical studies using this new quantitative biomarker in neurological diseases will show how to use it at its best.\n\nFOREWORDO_ST_ABSAbout OwkinC_ST_ABSOWKIN was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and Gilles Wainrib, PhD, a pioneer in the field of Artificial Intelligence in biology. OWKIN passed the proof-of-concept phase and is now providing its innovative AI algorithms to several of the largest cancer centers and pharmaceutical companies in Europe and in the US. With offices in New York and Paris, we pride ourselves in building a company culture around transparency, collaboration, challenge, optimism and fun.\n\nOwkins teamOwkins team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals.\n\nTasks repartitionIdea : Thomas Clozel, Roger Stup, Simon Jegou, Paul Herent\n\nBibliography : Paul Herent, Simon Jegou, Thomas Clozel\n\nData access : Simon Jegou, Paul Herent\n\nData cleaning : Simon Jegou, Paul Herent\n\nData analysis : Simon Jegou, Paul Herent\n\nData preprocessing : Simon Jegou, Paul Herent\n\nData analysis : Simon Jegou, Paul Herent\n\nTraining of models : Simon Jegou, Paul Herent\n\nWork on interpretability : Simon Jegou, Paul Herent\n\nWriting : Paul Herent\n\nRereading : Simon Jegou, Thomas Clozel, Julien Savatovsky, Roger Stupp, Olivier Elemento, Kim Gillier\n\nSubmission to medical congress : Paul Herent, Simon Jegou\n\nThanks to...\n\nSimon Jegou, for your mentoring in Machine Learning,\n\nThomas Clozel and Gilles Wainrib, for your welcome at Owkin, very benevolent, Roger Stupp, for your support and re-reading,\n\nJulien Savatovsky, for your support and re-reading,\n\nValentin Ame and Sylvain Toldo, for your help on the beautiful figures and the design of the related blogpost,\n\nAll the Owkin team members, for the great team work we did (and hope well do) between Paris and New York : Anna Huyghues Despointes, Anna I. Bondarenko, Pierre Courtiol, Derek T. Russell-Kraft, Cedric Whitney, Meriem Sefta, Vincent Lepage, Adrian Gonzalez, Maxime HE,Paul Jehanno, Raphael Leger, Alicia Simion, Eric Tramel, Mikhail Zaslavskiy, Pierre Manceron, Chloe Simpson, Paul Mabillot, Valentin Ame, Mathieu Galtier, Camille Marini, Sylvain Toldo, Charlie Saillard, Olivier Dehaene, Olivier Moindrot,\n\nPascal Roux, for your support, your help, your advices,\n\nAxelle, for your patience and support.

Explore related subjects

Keep this discovery

BibTeXRIS

Herent, P., Jegou, S., Wainrib, G., Clozel, T.. 2018-09-10. Brain age prediction of healthy subjects on anatomic MRI with deep learning: going beyond with an \"explainable AI\" mindset. https://doi.org/10.1101/413302

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience